このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Linvolseltamab (抗 BCMA x 抗 CD3 二重特異性抗体) と再発/難治性多発性骨髄腫 (LINKER-MM2) の参加者に対するその他のがん治療

2026年11月2日 更新者:Regeneron Pharmaceuticals

再発/難治性多発性骨髄腫患者に対する REGN5458 (抗 BCMA x 抗 CD3 二重特異性抗体) とその他のがん治療の第 1b 相試験

This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again.

In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies).

This study is the first time linvoseltamab will be combined with other cancer therapies.

The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination.

The study is looking at several other research questions, including:

  • How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma
  • What side effects may happen from taking linvoseltamab together with another cancer treatment
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)

調査の概要

研究の種類

介入

入学 (推定)

317

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • La Jolla、California、アメリカ、92037
        • 募集
        • Scripps Clinic Torrey Pines
    • Georgia
      • Atlanta、Georgia、アメリカ、30004
        • 募集
        • Winship Cancer Institute of Emory University
    • Indiana
      • Indianapolis、Indiana、アメリカ、46202
        • 募集
        • Indiana University Health Simon Cancer Center
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • 募集
        • Dana Farber/Harvard Cancer Center
    • Michigan
      • Detroit、Michigan、アメリカ、48201
        • 募集
        • Karmanos Cancer Institute
    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • 募集
        • Mayo Clinic
    • New York
      • New York、New York、アメリカ、10021
        • 募集
        • Weill Cornell Medicine/New York Presbyterian Hospital
      • New York、New York、アメリカ、10032
        • 募集
        • New York Presbyterian Hospital Columbia University Medical Center
    • North Carolina
      • Chapel Hill、North Carolina、アメリカ、27599
        • 募集
        • University of North Carolina at Chapel Hill
      • Winston-Salem、North Carolina、アメリカ、27157
        • 募集
        • Wake Forest University Health Sciences
    • Ohio
      • Columbus、Ohio、アメリカ、43210
        • 募集
        • The Ohio State University James Cancer Hospital
    • Texas
      • Dallas、Texas、アメリカ、75390
        • 募集
        • University of Texas Southwestern
    • Washington
      • Seattle、Washington、アメリカ、98108
        • 募集
        • VA Puget Sound Health Care System
      • Haifa、イスラエル、3109601
        • 募集
        • Rambam Health Care Campus
      • Jerusalem、イスラエル、91120
        • 募集
        • Hadassah Medical Center
    • Central District
      • Ramat Gan、Central District、イスラエル、5265601
        • 募集
        • Sheba Medical Center
      • Athens、ギリシャ、11528
        • 募集
        • General Hospital of Athens Alexandra
    • Attica
      • Athens、Attica、ギリシャ、10676
        • 募集
        • Evangelismos General Hospital
      • Barcelona、スペイン、08035
        • 募集
        • Hospital Universitario Vall d'Hebron
      • Barcelona、スペイン、08036
        • 募集
        • Hospital Clinic de Barcelona
      • Barcelona、スペイン、08908
        • 募集
        • Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals,
      • Madrid、スペイン、28050
        • 募集
        • Hospital Universitario HM Sanchinarro
      • Madrid、スペイン、28027
        • 募集
        • Clinica Universidad de Navarra - Madrid
      • Madrid、スペイン、28006
        • 募集
        • Universitaru Hospital La Princesa
      • Madrid、スペイン、28041
        • 募集
        • University Hospital and Research Institute
      • Madrid、スペイン、28034
        • 募集
        • Hospital Universitario Ramon y Cajal - Servicio de Psiquiatria
      • Salamanca、スペイン、37007
        • 募集
        • University Hospital of Salamanca
    • A Coruna
      • Santiago de Compostela、A Coruna、スペイン、15706
        • 募集
        • Hospital Clinico Universitario de Santiago
    • Barcelona
      • Badalona、Barcelona、スペイン、08916
        • 募集
        • Hospital Germans Trias i Pujol
    • Cantabria
      • Santander、Cantabria、スペイン、39008
        • 募集
        • Hospital Universitario Marques de Valdecilla
    • Madrid
      • Pozuelo de Alarcón、Madrid、スペイン、28223
        • 募集
        • Hospital Universitario Quiron Salud Madrid
    • Navarre
      • Pamplona、Navarre、スペイン、31008
        • 募集
        • Clinica Universidad de Navarra
      • Angers、フランス、49933
        • 募集
        • Centre Hospitalier Universitaire Angers
      • Montpellier、フランス、34295
        • 募集
        • CHU Montpellier - Departement D'Hematologie
      • Paris、フランス、75571
        • 募集
        • Saint Antoine Hospital
      • Villejuif、フランス、94805
        • 募集
        • Institut Gustave Roussy
    • New Aquitaine
      • Poitiers、New Aquitaine、フランス、86021
        • 募集
        • Centre Hospitalier Universitaire (CHU) de Poitiers
    • Nord
      • Lille、Nord、フランス、59037
        • 募集
        • CHU de Lille - Rue Michel Polonovski
    • Pays de la Loire Region
      • Nantes、Pays de la Loire Region、フランス、44093
        • 募集
        • Nantes University Hospital
    • Île-de-France Region
      • Créteil、Île-de-France Region、フランス、94000
        • 募集
        • Hospital Henri Mondor
      • Paris、Île-de-France Region、フランス、75015
        • 募集
        • Hopital Necker
      • Paris、Île-de-France Region、フランス、75010
        • 募集
        • Saint Louis Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

General Key Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  2. Participants must have measurable disease as defined in the protocol according to IMWG consensus criteria
  3. Adequate creatinine clearance, hematologic function and hepatic function, as defined in protocol
  4. Life expectancy of at least 6 months

Cohort Specific Inclusion Criteria:

For cohorts 1-6, each participant must have RRMM with progression following at least 3 lines of therapy, or at least 2 lines of therapy and either prior exposure to at least 1 anti-CD38 antibody, 1 immunomodulatory imide drug (IMiD) and 1 Proteasome Inhibitor (PI), or double-refractory to 1 PI and 1 IMiD, or the combination of 1 PI and 1 IMiD Cohort 1: Prior treatment with daratumumab is allowed if previously tolerated, as described in the protocol Cohort 2: Prior treatment with carfilzomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 3: Prior treatment with lenalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 4: Prior treatment with bortezomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 5: Prior treatment with pomalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 6: Prior treatment with isatuximab is allowed if previously tolerated, as described in the protocol

Cohort 7 and 8:

  1. For participants without measurable disease by biochemical parameters [serum or urine M-protein, or serum involved Free Light Chain (FLC)], presence of at least 1 soft tissue plasmacytoma with a single diameter of ≥2 cm
  2. RRMM with progressive disease and received at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI or triple-class refractory disease (anti-CD38 antibody, IMiD, PI) Cohort 9: Progressive RRMM in participants with triple-class refractory disease (anti-CD38 antibody, IMiD, PI) after at least 3 lines of therapy Cohort 10: Progressive RRMM after at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI

General Key Exclusion Criteria:

  1. Diagnosis of plasma cell leukemia, primary light-chain amyloidosis (excluding myeloma associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)
  2. Participants with known MM brain lesions or meningeal involvement
  3. Treatment with any systemic anti-myeloma therapy within 5 half-lives or within 21 days prior to first administration of study drug regimen, whichever is shorter
  4. History of allogeneic and autologous stem cell transplantation, as described in the protocol
  5. Unless stated otherwise in a specific sub-protocol, prior treatment with a T cell-based immunotherapy directed against B-Cell Maturation Antigen (BCMA) bispecific antibodies and Bispecific T-cell Engagers (BiTEs), and BCMA Chimeric Antigen Receptor (CAR) T cells (Note: BCMA antibody-drug conjugates are not excluded)
  6. History of progressive multifocal leukoencephalopathy, neurodegenerative condition or Central Nervous System (CNS) movement disorder or participants with a history of seizure within 12 months prior to study enrollment are excluded
  7. Live or attenuated vaccination within 28 days prior to first study drug regimen administration with a vector that has replicative potential
  8. Cardiac ejection fraction <40% by Echocardiogram (Echo) or Multigated Acquisition (MUGA) scan

Cohort Specific Exclusion Criteria:

Cohort 2: Dose expansion: Prior treatment with a BCMA-directed CAR T-cell therapy will not be exclusionary if completed at least 12 weeks prior to first study treatment Cohort 3: Known malabsorption syndrome or pre-existing gastrointestinal (GI) condition that may impair absorption of lenalidomide; delivery of lenalidomide via nasogastric tube or gastrostomy tube is not allowed Cohort 4: Peripheral neuropathy grade ≥2 Cohort 5: Known malabsorption syndrome or pre-existing GI conditions that may impair absorption of pomalidomide; delivery of pomalidomide via nasogastric tube or gastrostomy tube is not allowed

Cohort 7:

  1. Prior treatment with anti-Lymphocyte Activation Gene 3 (LAG-3) agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Programmed cell Death Protein 1 (PD-1) antibodies is permitted, as described in the protocol
  2. Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol
  3. Prior solid organ transplant
  4. History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies

Cohort 8:

  1. Prior treatment with anti-PD-1 or anti-PD-L1 agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) antibodies is permitted, as described in the protocol
  2. Encephalitis or meningitis in the year prior to enrollment
  3. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to enrollment
  4. Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol.
  5. Prior solid organ transplant
  6. History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies

Cohort 9:

  1. Abnormal QT interval corrected by Fridericia's formula (QTcF), as described in the protocol
  2. Use of concomitant medications that are known to prolong the QT/QTcF interval including Class Ia and Class III antiarrhythmics at the time of informed consent
  3. Ongoing use or anticipated use of food or drugs that are known strong/moderate cytochrome P450 (CYP)3A4 inhibitors, or strong CYP3A inducers within 14 days prior to first dose of nirogacestat
  4. Known malabsorption syndrome or existing gastrointestinal GI condition that may impair absorption of nirogacestat; delivery of nirogacestat via nasogastric tube or gastrostomy tube is not allowed

Cohort 10:

  1. Known or suspected active Epstein-Barr Virus (EBV) infection
  2. Known history of Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)
  3. Prior treatment with cevostamab or another agent with the same target [Fragment crystallizable Receptor-like 5 (FcRH5)]

Dose finding portion: Prior treatment with any BCMA-directed immunotherapy will not be exclusionary, as described in the protocol Dose expansion portion: Prior treatment with any T cell-engaging bispecific antibody directed against BCMA will be exclusionary, as described in the protocol

NOTE: Other protocol defined inclusion/exclusion criteria apply

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort 1: Linvoseltamab + Daratumumab

Linvoseltamab + Daratumumab

Administered per the protocol

他の名前:
  • REGN5458
  • Lynozyfic™

Administered per the protocol

他の名前:
  • Darzalex®;ダーザレックス ファスプロ™
実験的:Cohort 2: Linvoseltamab + Carfilzomib

Linvoseltamab + Carfilzomib

Administered per the protocol

他の名前:
  • REGN5458
  • Lynozyfic™

Administered per the protocol

他の名前:
  • カイプロリス®
実験的:Cohort 3: Linvoseltamab + Lenalidomide

Linvoseltamab + Lenalidomide

Administered per the protocol

他の名前:
  • REGN5458
  • Lynozyfic™

Administered per the protocol

他の名前:
  • レブリミド®
実験的:Cohort 4: Linvoseltamab + Bortezomib

Linvoseltamab + Bortezomib

Administered per the protocol

他の名前:
  • REGN5458
  • Lynozyfic™

Administered per the protocol

他の名前:
  • ベルケード®
実験的:Cohort 5: Linvoseltamab + Pomalidomide

Linvoseltamab + Pomalidomide

Administered per the protocol

他の名前:
  • REGN5458
  • Lynozyfic™

Administered per the protocol

他の名前:
  • イムノビッド、ポマリスト®
実験的:Cohort 6: Linvoseltamab + Isatuximab

Linvoseltamab + Isatuximab

Administered per the protocol

他の名前:
  • REGN5458
  • Lynozyfic™

Administered per the protocol

他の名前:
  • サルクリサ®
実験的:Cohort 7: Linvoseltamab + Fianlimab

Linvoseltamab + Fianlimab

Administered per the protocol

他の名前:
  • REGN5458
  • Lynozyfic™

Administered per the protocol

他の名前:
  • REGN3767
実験的:Cohort 8: Linvoseltamab + Cemiplimab

Linvoseltamab + Cemiplimab

Administered per the protocol

他の名前:
  • REGN5458
  • Lynozyfic™

Administered per the protocol

他の名前:
  • REGN2810
  • リバヨ
実験的:Cohort 9: Linvoseltamab + Nirogacestat

Linvoseltamab + Nirogacestat

Administered per the protocol

他の名前:
  • REGN5458
  • Lynozyfic™

Administered per the protocol

他の名前:
  • PF-03084014
実験的:Cohort 10: Linvoseltamab + Cevostamab

Linvoseltamab + Cevostamab

Administered per the protocol

他の名前:
  • REGN5458
  • Lynozyfic™

Administered per the protocol

他の名前:
  • RO7187797
  • BFCR4350A

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
重大な有害事象(SAE)の発生率
時間枠:5年まで
5年まで
TEAEの重症度
時間枠:最長5年
最長5年
SAEの重症度
時間枠:最長5年
最長5年
AESI の重大度
時間枠:最長5年
最長5年
Incidence of Treatment-Emergent Adverse Events (TEAEs)
時間枠:Up to 5 Years
Up to 5 Years
Incidence of Adverse Events of Special Interest (AESIs)
時間枠:Up to 5 Years
Up to 5 Years
Incidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation period
時間枠:Up to 28 Days

Dose finding portion only

Up to 28 Days
Incidence of laboratory abnormalities
時間枠:Up to 5 Years

≥ grade 3 per National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE v5.0]

Up to 5 Years

二次結果の測定

結果測定
時間枠
全生存期間 (OS)
時間枠:5年まで
5年まで
経時的な血清中の総リンボセルタマブ濃度
時間枠:最長5年
最長5年
Overall Response Rate (ORR) as measured by International Myeloma Working Group (IMWG) criteria
時間枠:Up to 5 Years
Up to 5 Years
Duration of Response (DOR) by IMWG criteria
時間枠:Up to 5 Years
Up to 5 Years
Progression-Free Survival (PFS) as measured by IMWG criteria
時間枠:Up to 5 Years
Up to 5 Years
Rate of Minimal Residual Disease (MRD) negative status by IMWG criteria
時間枠:Up to 5 Years
Up to 5 Years
Incidence over time of Anti-Drug Antibodies (ADAs) to linvoseltamab
時間枠:Up to 5 Years
Up to 5 Years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Clinical Trial Management、Regeneron Pharmaceuticals

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年8月17日

一次修了 (推定)

2028年3月25日

研究の完了 (推定)

2032年3月24日

試験登録日

最初に提出

2021年11月18日

QC基準を満たした最初の提出物

2021年11月18日

最初の投稿 (実際)

2021年11月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD 共有時間枠

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD 共有アクセス基準

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する